Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

End-of-day quote. End-of-day quote  - 03/04
55.605 USD   +0.31%
09/21DJMylan CEO Faces Tough Questioning in EpiPen Hearing
09/21 MYLAN : shares languish at low valuation as EpiPen hearing nears
09/21 MEDICARE EPIPEN : Kaiser report
Financials ($)
Sales 2016 11 224 M
EBIT 2016 3 313 M
Net income 2016 1 698 M
Debt 2016 10 849 M
Yield 2016 -
Sales 2017 13 252 M
EBIT 2017 4 079 M
Net income 2017 2 421 M
Debt 2017 10 984 M
Yield 2017 -
P/E ratio 2016 14,74
P/E ratio 2017 10,33
EV / Sales2016 2,97x
EV / Sales2017 2,53x
Capitalization 22 498 M
More Financials
Mylan N.V., is a pharmaceutical company which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted primarily in the U.S. and... 
10/27Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
09/21DJMylan CEO Faces Tough Questioning in EpiPen Hearing
09/21 MYLAN : U.S. Senate finance committee asks for Mylan EpiPen rebate investigation
09/21 MYLAN : shares languish at low valuation as EpiPen hearing nears
09/15DJMYLAN : EpiPen Maker Executive to Testify at House Hearing
09/12 Activist Starboard demands rapid changes at Perrigo
09/12DJStarboard Value Takes 4.6% Stake in Perrigo
09/06 MYLAN : New York to probe Mylan EpiPen contracts for schools
09/02DJU.S. Stocks Advance, but Drugmakers Falter
09/01 MYLAN : Weak Mylan board fosters EpiPen 'debacle' - New York comptroller
More news
Sector news : Pharmaceuticals - NEC
03:00p Pfizer abandons plan to split into two companies
01:53pDJPFIZER : Won't Pursue a Split of Established and New Medical Lines -- Update
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
06:57aDJPFIZER : Won't Pursue a Split
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 56,6 $
Spread / Average Target 34%
Consensus details
EPS Revisions
More Estimates Revisions
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%22 498
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results